

Modified Form PTO-1449

Atty. Docket No.

3369-A

Serial No.

10/712.122

Applicant

John D. PLUENNEKE

Filing Date

November 13, 2003

Group

1614

**LIST OF REFERENCES CITED BY APPLICANT**

JUN 01 2004

(use several sheets if necessary)

**U.S. PATENT DOCUMENTS**

EXAMINER/REFEREE INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
CR	A1 2002/0001587	01/03/2002	Erickson et al.			
	A2 2002/0012663	01/31/2002	Waksal			
	A3 2002/0034736	03/21/2002	Falb et al.			
	A4 2002/0058033	05/16/2002	Raisch et al.			
	A5 2002/0065398	05/30/2002	del Rio et al.			
	A6 2002/0102685	08/01/2002	Sibilia et al.			
	A7 2002/0107284	08/08/2002	Uckun et al.			
	A8 5,183,805	02/02/1993	Lee et al.			
	A9 5,459,061	10/17/1995	Sato et al.			
	A10 5,558,864	09/24/1996	Bendig et al.			
	A11 5,770,195	06/23/1998	Hudziak			
	A12 5,844,093	12/01/1998	Kettleborough et al.			
	A13 5,874,528	02/23/1999	Lupu et al.			
	A14 5,891,996	04/06/1999	del Rio et al.			
	A15 5,894,018	04/13/1999	Davila et al.			
	A16 5,914,269	06/22/1999	Bennett et al.			
	A17 5,981,725	11/09/1999	Vogelstein et al.			
	A18 6,057,156	05/02/2000	Akhtar et al.			
	A19 6,127,344	10/03/2000	Amici et al.			
	A20 6,129,915	10/10/2000	Wels et al.			
	A21 6,187,585	02/13/2001	Bennett et al.			
	A22 6,217,866	04/17/2001	Schlessinger et al.			
	A23 6,224,868	05/01/2001	Wong et al.			
CR	A24 6,235,883	05/22/2001	Jakobovits et al.			

EXAMINER:

Date Considered:

10/06/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modified Form PTO-1449

Atty. Docket No.

3369-A

Serial No.

10/712.122

**LIST OF REFERENCES CITED BY APPLICANT**

(Continued)

Applicant

John D. PLUENNEKE

Filing Date

November 13, 2003

Group

1614

**FOREIGN PATENT DOCUMENTS**

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES      NO
CR	B1	0 566 226 B1	11/08/1995	EP			
	B2	0 667 165 B1	03/27/2002	EP			
	B3	1 170 011 A1	01/09/2002	EP			
	B4	WO 95/20045	07/27/1995	PCT			
	B5	WO 95/24190	09/14/1995	PCT			
	B6	WO 96/30347	10/03/1996	PCT			
	B7	WO 96/40648	12/19/1996	PCT			
CR	B8	WO 97/41226	11/06/1997	PCT			
	B9						

EXAMINER'S INITIALS

**OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)**

CR	C1	Boccardo F et al., "Intracystic epidermal growth factor level is predictive of breast-cancer risk in women with gross cystic disease of the breast," <i>Int J Cancer (Pred Oncol)</i> ; 95:260-265, 2001.
	C2	Ciardiello F and Tortora G, "A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor," <i>Clin Cancer Res</i> , 7:2958-2970, 2001.
	C3	Crombet-Ramos T et al., "Pharmacological and clinical evaluation of the humanized anti EGF-R monoclonal antibody, h-R3, in patients with advanced epithelial carcinomas," 2001 ASCO Annual Meeting, May 12-15, 2001, San Francisco, CA, Abstract No. 1012.
	C4	Di Lieto A et al., "EGF/EGF-R system and benign breast disease during and following the treatment of gynaecological pathologies with an analogue of LH-RH," <i>Clin Exp Obst Gyn</i> , XXIII(4):220-228, 1996.
	C5	Dorrance AM et al., "Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats," <i>Am J Physiol Regulatory Integrative Comp Physiol</i> , 281:R944-R950, 2001.
	C6	Heldin C-H, "Signal transduction: multiple pathways, multiple options for therapy," <i>Stem Cells</i> 19:295-303, 2001.
	C7	Hess JC et al., "Growth factor profiles in breast cyst fluid identify women with increased breast cancer risk," <i>Am J Surg</i> , 167:523-530, 1994.
	C8	Justicia C and Planas AM, "Transforming growth factor- $\alpha$ acting at the epidermal growth factor receptor reduces infarct volume after permanent middle cerebral artery occlusion in rats," <i>J Cereb Blood Flow Metab</i> , 19:128-132, 1999.
CR	C9	Miyazaki Y et al., "Gastrin induces heparin-binding epidermal growth factor-like growth factor in rat gastric epithelial cells transfected with gastrin receptor," <i>Gastroenterology</i> , 116:78-89, 1999.

EXAMINER:

Date Considered:


10/06/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modified Form PTO-1449		Atty. Docket No. 3369-A	Serial No. 10/712.122
<b>LIST OF REFERENCES CITED BY APPLICANT</b>  (Continued)		Applicant John D. PLUENNEKE	
		Filing Date November 13, 2003	Group 1614

**EXAMINER'S INITIALS**      **OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)**

CJ	C10	Nicholson RI et al., "EGFR and cancer prognosis," <i>Eur J Cancer</i> , 37:S9-S15, 2001.
	C11	Nishi E et al., "Lysophosphatidylcholine increases expression of heparin-binding epidermal growth factor-like growth factor in human T lymphocytes," <i>Circ Res</i> , 80:638-644, 1997.
	C12	Noble F et al., "International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors," <i>Pharmacol Rev</i> , 51(4):745-781, 1999.
	C13	Pavelic K et al., "Evidence for a role of EGF receptor in the progression of human lung carcinoma," <i>Anticancer Res</i> , 13:1133-1138, 1993.
	C14	Rozengurt E and Walsh JH, "Gastrin, CCK, signaling, and cancer," <i>Annu Rev Physiol</i> 63:49-76, 2001.
	C15	Sambhi MP et al., "Increased EGF binding and EGFR mRNA expression in rat aorta with chronic administration of pressor angiotensin II," <i>Biochem Med Metab Biol</i> , 48:8-18, 1992.
	C16	Schaer J-C and Reubi JC, "High gastrin and cholecystokinin (CCK) gene expression in human neuronal, renal, and myogenic stem cell tumors: comparison with CCK-A and CCK-B receptor contents," <i>J Clin Endocrinol Metab</i> , 84:233-239, 1999.
	C17	Shaw JP et al., "Cytotoxic properties of DAB <sub>488</sub> -EGF and DAB <sub>389</sub> -EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins," <i>J Biol Chem</i> , 266(31):21118-21124, 1991.
	C18	Smith AM et al., "Phase I/II study of G17-DT, an anti-gastrin immunogen, in advanced colorectal cancer," <i>Clin Cancer Res</i> , 6:4719-4724, 2000.
	C19	Smith AM and Watson SA, "Gastrin and gastrin receptor activation: an early event in the adenoma-carcinoma sequence," <i>Gut</i> , 47:820-824, 2000.
	C20	Swaminathan N et al., "Elevated epidermal growth factor receptor levels in hypertensive Lyon rat kidney and aorta," <i>Clin Exp Pharmacol Physiol</i> , 23:793-796, 1996.
	C21	Ullrich A et al., "Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells," <i>Nature</i> , 309:418-425, 1984.
	C22	Watson SA et al., "Transforming growth factor-a-mediated growth pathways in human gastro-intestinal cell lines in relation to the gastrin autocrine pathway," <i>Int J Cancer</i> , 87:20-28, 2000.
CJ	C23	Zwick E et al., "Receptor tyrosine kinase signalling as a target for cancer intervention strategies," <i>Endocrine-Related Cancer</i> , 8:161-173, 2001.
	C24	
	C25	
	C26	

EXAMINER:	Date Considered:
	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	